Ichor Biologics

423W 127th St

New York, NY 10027

©2019 by Ichor Biologics. 

Media & Press Updates

Being part of the biotechnology field means we operate in a fast-paced world where changes happen often and quickly. This media section includes all the exciting news and updates about Ichor Biologics, as well as industry news and analysis. If you have any questions about our articles, please get in touch today.

Ichor is awarded $300,000 to develop therapeutics to treat hantavirus infections.

May 1, 2019

Ichor Biologics receives a $300,000 grant from the National Institutes of Health to utilize its platform technology to develop broadly neutralizing antibodies against deadly hantavirus infections.

Ichor develops therapeutic to treat one of the most deadly strains of hantavirus infections

November 21, 2018

In findings published in Science Translational Medicine (Garrido et al.), scientists at Ichor Biologics -- in collaboration with researchers from the NIH and University of Concepción in Chile -- demonstrate that Ichor's two lead antibody-based drugs protect 100% of animals against lethal hantavirus infections.

Ichor is selected to participate in the 2017 NYC Economic Development Corporation Entrepreneurship Laboratory (eLab) Program

January 10, 2017

Ichor was selected to participate in the NYC EDC's competitive entry eLab program, which selects 12 NYC-based biotechnology start-ups to participate in a 7 month mini biotechnology MBA program. 

Ichor Biologics and the University of Concepcion

are awarded $250,000 by the Chilean government.

March 1, 2017

In collaboration with researchers from the University of Concepcion in Chile, Ichor has been awarded $250,000 by the Chilean government's Scientific and Technological Development Support Fund (FONDEF) to  extend it's program to develop therapeutics against deadly Andes hantavirus infections.

Ichor wins Celdara Medical's best pitch competition 2016

December 14, 2016

Participants pitch their business ideas in front of biotechnology industry leaders and investors to compete for the best pitch prize.

Ichor Biologics and the University of Concepcion 

are awarded $300,000 to develop therapeutics against hantavirus

March 1, 2015

In collaboration with researchers from the University of Concepcion in Chile, Ichor has been awarded $300,000 by the Chilean govenment's Scientific and Technological Development Support Fund (FONDEF) to use it's antibody development platform to generate therapeutics against Andes hantavirus infections.